Search company, investor...
Search
Alnylam Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

alnylam.com

Founded Year

2002

Stage

Corporate Minority - P2P | IPO

Total Raised

$67.32M

Market Cap

24.10B

Stock Price

200.78

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are many new therapeutic frontiers for its RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics.

Alnylam Pharmaceuticals Headquarters Location

300 Third Street 3rd Floor

Cambridge, Massachusetts, 02142,

United States

617-551-8200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Alnylam Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Alnylam Pharmaceuticals in 1 CB Insights research brief, most recently on Nov 25, 2019.

Expert Collections containing Alnylam Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alnylam Pharmaceuticals is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Alnylam Pharmaceuticals Patents

Alnylam Pharmaceuticals has filed 527 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/4/2019

9/20/2022

Transcription factors, Kidney diseases, Human proteins, Oxalates, Metabolism

Grant

Application Date

11/4/2019

Grant Date

9/20/2022

Title

Related Topics

Transcription factors, Kidney diseases, Human proteins, Oxalates, Metabolism

Status

Grant

Latest Alnylam Pharmaceuticals News

Sharma and Lippman join Alnylam C-suite

Sep 22, 2022

Sharma and Lippman join Alnylam C-suite Plus Shah now COO at Precigen and updates from Carmot, Evozyne, Matinas, Maxwell and more By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst  September 21, 2022 9:00 PM UTC Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) hired Piyush Sharma as chief ethics and compliance officer and Evan Lippman as chief corporate development and strategy officer, a newly created role. Sharma joins Alnylam from Alexion Pharmaceuticals Inc., where he was head of compliance. He also held various compliance positions at Pfizer Inc. (NYSE:PFE), including chief compliance counsel for the oncology and emerging markets business. Lippman was president and COO at Intima Bioscience Inc. and SVP, head of corporate development, M&A and valuation for Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Cell and gene therapy company  Precigen Inc. (NASDAQ:PGEN) hired Rutul Shah as COO, also a newly created role, effective Oct. 1. Shah joined Precigen in 2014 and has served in roles of increasing responsibility, most recently as head of operations and portfolio. ... BCIQ Company Profiles

Alnylam Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alnylam Pharmaceuticals Rank

  • When was Alnylam Pharmaceuticals founded?

    Alnylam Pharmaceuticals was founded in 2002.

  • Where is Alnylam Pharmaceuticals's headquarters?

    Alnylam Pharmaceuticals's headquarters is located at 300 Third Street, Cambridge.

  • What is Alnylam Pharmaceuticals's latest funding round?

    Alnylam Pharmaceuticals's latest funding round is Corporate Minority - P2P.

  • How much did Alnylam Pharmaceuticals raise?

    Alnylam Pharmaceuticals raised a total of $67.32M.

  • Who are the investors of Alnylam Pharmaceuticals?

    Investors of Alnylam Pharmaceuticals include Blackstone, Roche Venture Fund, Novartis Venture Funds, Polaris Partners, Cardinal Partners and 5 more.

  • Who are Alnylam Pharmaceuticals's competitors?

    Competitors of Alnylam Pharmaceuticals include EQRx, Ra Pharmaceuticals, SynDevRx, The Medicines Company, Entelos and 12 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Konova Logo
Konova

Konova offers anti-obesity drug development

S
SynDevRx

SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market, and inhibits MetAP2 - an enzyme which independent research has shown to be key to tumor growth, proliferation and metastasis.

A
Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

C
Cellogico

Cellogico Simulations Allow More Efficient Use Of Resources Through Highlighting Drug Targets With The Greatest Chance Of Success In The Early Stage Of Drug Development.

S
Salzburg Therapeutics

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.